Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 17/20 | 0.82 |
| ▸ | MMP13 | P45452 | 15/20 | 0.64 |
| ▸ | MMP1 | P03956 | 14/20 | 0.64 |
| ▸ | MMP9 | P14780 | 14/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6263654 | 0.92 | ADAM17 (0.82) | ADAM17MMP13MMP1MMP9 | |
| Hydroxyamine SCHEMBL4026602 | 0.91 | ADAM17 (0.83) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6261771 | 0.91 | ADAM17 (0.86) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6702006 | 0.91 | ADAM17 (0.81) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6262973 | 0.90 | ADAM17 (1.00) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6704851 | 0.85 | ADAM17 (0.80) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL4033569 | 0.84 | ADAM17 (0.82) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6268614 | 0.83 | ADAM17 (0.78) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6262928 | 0.82 | ADAM17 (0.81) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL4033702 | 0.82 | ADAM17 (0.60) | ADAM17MMP13MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488754-B2 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | WYETH | 2004-11-18 | — | — | US | disclosed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | ADAM17 9/4885MMP13 246/4885MMP1 215/4885 |
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | MMP17, MMP1, MMP9 | ADAM17 12/4885MMP13 16/4885MMP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.